Immunogenicity of long-lasting recombinant factor VIII products

Cell Immunol. 2016 Mar;301:40-8. doi: 10.1016/j.cellimm.2015.12.006. Epub 2015 Dec 19.


Replacement therapy for patients with hemophilia A using plasma-derived or recombinant factor VIII (FVIII) is complicated by the short half-life of the FVIII products and by the occurrence of neutralizing antibodies in a substantial number of patients. In the recent years, enormous efforts have been invested to develop new generations of coagulation factors with extended half-lives. Presumably, the use of long-lasting FVIII products should reduce the frequency of administration to the patients and drastically improve their quality of life. The question of their immunogenicity remains however unanswered as yet. The present review proposes a summary of the different strategies developed to enhance the half-life of FVIII, including fusion of FVIII to the Fc fragment of the human IgG1 or to human serum albumin, or attachment of polyethylene glycol. Based on the available literature, we hypothesize on the potential benefits or risks associated with each of the latter strategies in terms of immunogenicity of the newly derived hemostatic drugs.

Keywords: Albumin fusion; Coagulation factor; Factor VIII; Fc fusion; Hemophilia; Immunogenicity; Long-lasting; PEGylation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Factor VIII / immunology*
  • Factor VIII / metabolism
  • Factor VIII / pharmacokinetics*
  • Half-Life
  • Hemophilia A / immunology*
  • Humans
  • Recombinant Fusion Proteins / immunology*
  • Recombinant Fusion Proteins / metabolism
  • Recombinant Fusion Proteins / pharmacokinetics*


  • Recombinant Fusion Proteins
  • Factor VIII